Alvarez-Reguera, C.Calderon-Goercke, M.Loricera, J.Moriano, C.Castaneda, S.Narvaez, J.Aldasoro, V.Maiz, O.Melero, R.Villa-Blanco, I.Vela-Casasempere, P.Romero-Yuste, S.Callejas-Rubio, J. L.De Miguel, E.Galindez-Agirregoikoa, E.Sivera, F.Fernandez-Lopez, C.Galisteo, C.Ferraz-Amaro, I.Sanchez-Martin, J.Sanchez-Bilbao, L.Hernandez Hernandez, J. L.Gonzalez-Gay, M. A.Blancoon, R.Tocilizumab Giant Cell Arteritis S2023-05-032023-05-032022-06-010003-4967http://hdl.handle.net/10668/20098enOPTIMIZATION OF TOCILIZUMAB THERAPY IN GIANT CELL ARTERITIS. A MULTICENTER REAL-LIFE STUDY OF 471 PATIENTS.conference outputopen access10.1136/annrheumdis-2022-eular.32791468-2060https://ard.bmj.com/content/annrheumdis/81/Suppl_1/692.2.full.pdf850279002339